サンディーノの実像と英雄像をめぐるニカラグア・ナショナリズムの一考察

Augusto Sandino, "Father of the liberation of Nicaragua" and leader of an armed guerilla band assassinated in 1934, conceptualized the Nicaraguans as the "indian-hispanic-americans," and attached great importance to this hybridity. This concept derived from the idea of indigenismo, which was used to support the incorporation of ethnic groups into white creole\u27s "national" framework. In this sense, Sandino shared a typical "liberal" thought with the contemporary intellectuals, and refused revolutionary thoughts. Carlos Fonseca, who established the Sandinista Front for National Liberation (FSLN) in 1961, presented Sandino as the new "National Hero" for the Nicaraguan people. For Fonseca, Sandino\u27s antiimperialistic and nationalistic words and actions, were potent national symbols that justified the FSLN\u27s guerilla movements against the dictatorship of the Somoza family and its storng supporter, the United States. Fonseca added a socialistic and revolutionary image to Sandino who never aimed at socialism nor revolution. Fonseca also tried to create a "National History " stretching from Sandino\u27s historic rebellion up to the achivement of the soon-to-be-realized revolution by the FSLN in 1979

RNA-binding protein ptbp1 regulates alternative splicing and transcriptome in spermatogonia and maintains spermatogenesis in concert with nanos3

Manami SENOO, Hiroshi HOZOJI, Yu ISHIKAWA-YAMAUCHI, Takashi TAKIJIRI, Sho OHTA, Tomoyo UKAI, Mio KABATA, Takuya YAMAMOTO, Yasuhiro YAMADA, Masahito IKAWA, Manabu OZAWA, RNA-binding protein Ptbp1 regulates alternative splicing and transcriptome in spermatogonia and maintains spermatogenesis in concert with Nanos3, Journal of Reproduction and Development, 2020, Volume 66, Issue 5, Pages 459-467, Released October 13, 2020, [Advance publication] Released July 06, 2020, Online ISSN 1348-4400, Print ISSN 0916-8818, https://doi.org/10.1262/jrd.2020-060, https://www.jstage.jst.go.jp/article/jrd/66/5/66_2020-060/_article/-char/e

Enhanced Recombinant Protein Productivity by Genome Reduction in Bacillus subtilis

The emerging field of synthetic genomics is expected to facilitate the generation of microorganisms with the potential to achieve a sustainable society. One approach towards this goal is the reduction of microbial genomes by rationally designed deletions to create simplified cells with predictable behavior that act as a platform to build in various genetic systems for specific purposes. We report a novel Bacillus subtilis strain, MBG874, depleted of 874 kb (20%) of the genomic sequence. When compared with wild-type cells, the regulatory network of gene expression of the mutant strain is reorganized after entry into the transition state due to the synergistic effect of multiple deletions, and productivity of extracellular cellulase and protease from transformed plasmids harboring the corresponding genes is remarkably enhanced. To our knowledge, this is the first report demonstrating that genome reduction actually contributes to the creation of bacterial cells with a practical application in industry. Further systematic analysis of changes in the transcriptional regulatory network of MGB874 cells in relation to protein productivity should facilitate the generation of improved B. subtilis cells as hosts of industrial protein production

Transient increase in systemic interferences in the superficial layer and its influence on event-related motor tasks: a functional near-infrared spectroscopy study

Abstract. Functional near-infrared spectroscopy (fNIRS) is a widely utilized neuroimaging tool in fundamental neuroscience research and clinical investigation. Previous research has revealed that task-evoked systemic artifacts mainly originating from the superficial-tissue may preclude the identification of cerebral activation during a given task. We examined the influence of such artifacts on event-related brain activity during a brisk squeezing movement. We estimated task-evoked superficial-tissue hemodynamics from short source–detector distance channels (15 mm) by applying principal component analysis. The estimated superficial-tissue hemodynamics exhibited temporal profiles similar to the canonical cerebral hemodynamic model. Importantly, this task-evoked profile was also observed in data from a block design motor experiment, suggesting a transient increase in superficial-tissue hemodynamics occurs following motor behavior, irrespective of task design. We also confirmed that estimation of event-related cerebral hemodynamics was improved by a simple superficial-tissue hemodynamic artifact removal process using 15-mm short distance channels, compared to the results when no artifact removal was applied. Thus, our results elucidate task design-independent characteristics of superficial-tissue hemodynamics and highlight the need for the application of superficial-tissue hemodynamic artifact removal methods when analyzing fNIRS data obtained during event-related motor tasks

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension